Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02970968 · ClinicalTrials.gov registry record · Phase 2

Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis

A Phase 2 study of Gastroparesis, sponsored by Vanda Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
152
Enrollment target
20
Study locations

NCT02970968 is a Phase 2 study of Gastroparesis that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 152 participants, below the 299-participant average among 44 other Gastroparesis trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02970968, a Phase 2 study of Gastroparesis, has completed, sponsored by Vanda Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
152 participants
Enrollment target
20
Study locations

Study Summary

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will be randomized to one of two treatment groups, active or placebo.

Conditions Studied

Gastroparesis

Interventions

  • OTHER Placebo
  • DRUG VLY-686 (Tradipitant)

Study Locations (20)

California

  • Vanda Investigational Site - Chula Vista
  • Vanda Investigational Site - Los Angeles
  • Vanda Investigational Site - Palo Alto
  • Vanda Investigational Site - San Francisco

Florida

  • Vanda Investigational Site - Jacksonville
  • Vanda Investigational Site - Largo
  • Vanda Investigational Site - Miami

Alabama

  • Vanda Investigational Site - Dothan
  • Vanda Investigational Site - Huntsville

Massachusetts

  • Vanda Investigational Site - Boston
  • Vanda Investigational Site - Boston

Arizona

  • Vanda Investigational Site - Tucson

Arkansas

  • Vanda Investigational Site - Little Rock

Georgia

  • Vanda Investigational Site - Athens

Illinois

  • Vanda Investigational Site - Elgin

Trial Details

FieldValue
Enrollment Target 152 participants
Start Date 2016-11
Est. Completion 2018-12
Phase Phase 2

Sponsor

Vanda Pharmaceuticals

68 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02970968

The ClinicalTrials.gov registry entry for NCT02970968 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 299-participant average among 44 other Gastroparesis trials with a reported enrollment target (49% lower). The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Gastroparesis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02970968 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT02970968 about?

NCT02970968 is a clinical study titled "Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis". This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will be randomized to one of two treatment groups, active or placebo.

What is the current status of trial NCT02970968?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2016-11. Estimated completion is 2018-12.

What conditions does trial NCT02970968 study?

This clinical trial studies the following conditions: Gastroparesis.

What interventions are being tested in trial NCT02970968?

The interventions under investigation include: Placebo (OTHER), VLY-686 (Tradipitant) (DRUG).

Who is sponsoring clinical trial NCT02970968?

This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02970968 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastroparesis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastroparesis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.